Member Info for PL75

Bein, the main adverse event was tiredness…

‘One of his patients, in fact, the patient with the d-partial response that we'll talk about in the next slide, this adverse event, as he moved through the trial, was that he was tired of coming to the clinic every week. He was trying to get back to his work life. ‘

Tiredness of having to go and get treatment.

Gje, you’re responding. Bin or report and ignore is the best advice.

Starter kit:

LivedataaccountsheppyGeneralOzJWBellamyWatching2Viking.RaiderSlacker246TheValueCurveTrendzD-GeemanIcecoolToukankahmoonThornogsonwyndrum

and many many more…

Right, so everyone is agreed. They’re twats that are here to disrupt, there is absolutely no other reason - 100% agenda driven. Only one answer. Bin, report and ignore. Same goes for fluffers.

Rambo, good summary of Alan's approach, why would he change it when it's funding his lifestyle. I disagree that right now they should look too far beyond ava6k.

They have a lovely poster, brochures available, for affimers calling out why they're superior. It's achieved nothing. They could produce the same for precision, now rebranded for a comparison against ADCs, showing how great the platform is. They need a commercial product out there proving it. Switching the pipeline to compete with ADCs isn't cheap, they're spending a lot on R&D. Personally I'd rather see them do that once they're self sustaining rather than diluting.

12) Seemingly no bank holidays IN THE ROOM. Poor sods. Tough times in TWs sweat shop. Give them a day off you heartless toothless animal.

Fluffer

They all do it, they love lying to get attention. Sad twats.

‘despite recent successes’. ADCs don’t sound that successful when you compare them to AVA6k and the bloke whose main complaint is having the rigmarole of having to traipse in for treatment as he’s feeling on top of the world. That’s a success.

Evening, that slide was the clear highlight for me. Very well communicated as the previous Alan explainer didn’t make it clear that it works perfectly for both mid and high fap. Opens up lots of opportunities for the proven platform.

Disappointed the bot didn’t post it first. Praise given where it’s due, as always

Have been shopping…. $1bn for preclinical. Thanks to Rah for sharing on twatter.

https://www.reuters.com/business/healthcare-pharmaceuticals/novartis-buy-radiology-specialist-mariana-oncology-1-billion-2024-05-02/

Lolz a plenty if one of the options that’s back on the table is agreeing to a takeover. I’d suggest a bit more than $1bn given platform technologies and being in the clinic. You could imagine Alan digging his heels in and you could imagine Chris thinking a quick payday could work out nicely.

I don't think Apicel is irrelevant to Abakta, it still holds a value. If the value can be unlocked then it's a winner. There could be a bigger appetite for investing over there and we can gain from it. If not, nothing ventured....

FFS. Another potentially interesting thread now just a collection of green box twats noshing each other off. Thanks for trying Ronny.

*hanging.

This laggy mess of a website leads to a lot of tpyos nooowadys. Paiful stiff

I imagine it’s an option. Apicel aren’t having around though, it be fascinating to see how it gets on in the clinic. An IPO could serve the same purpose, a chance to retain some ownership and get some capital for Tx coffers.

He didn't like the Paul Hill interview as Paul went off script and asked him about the commercial strategy - for clout obviously. Not only did Alan have a face like thunder he stumbled and thoroughly embarrassed himself - not a good sign for a CEO. Whatever, he's gone.

Chris refers to herself as Chris. I'm sure over time she'll adopt other names, much like Alan, who used to call himself SirAl, WaffAl and even Alastair occasionally.

Thanks Timster, I'll give it a try

Timster, can you explain further?